Madrid, Spain
Madrid, Spain

Time filter

Source Type

ST. LOUIS, Março 3, 2017 /PRNewswire/ -- MediBeacon Inc., uma empresa do portfólio na plataforma da Pansend Life Sciences da HC2 Holdings, Inc. (NYSE MKT: HCHC), anunciou hoje a conclusão bem-sucedida de um estudo clínico no local de atendimento e em tempo real de indivíduos com insuficiência renal realizado na Washington University em St. Louis. Durante o estudo clínico, foi medida a função renal de indivíduos compreendidos entre a faixa de normal até ao Estágio 4 de Doença Renal Crónica (DRC). O estudo também incluiu ainda indivíduos do St. Louis University Hospital. A proposta de Monitor da Taxa de Filtragem Glomerular Transdérmica ("GFR") da MediBeacon's utiliza um sensor ótico de pele combinado com um agente marcador fluorescente proprietário que brilha na presença da luz. O sistema foi desenhado para fornecer aos profissionais de saúde uma monitorização contínua e em tempo real da função renal, sem a necessidade de amostras de sangue. "A conclusão do nosso estudo clínico em pacientes com insuficiência da função renal representa um marco importante", afirmou Steve Hanley, CEO da MediBeacon. "Prevemos iniciar o nosso estudo clínico multicêntrico em locais nos Estados Unidos e na Europa durante o quarto trimestre de 2017." As amostras de sangue recolhidas atualmente em consultórios médicos fornecem apenas estimativas com atraso e com uma variabilidade que pode resultar em imprecisões. "Os métodos para a avaliação da função renal não sofreram alterações nos últimos 25 anos", disse o Dr. Richard Solomon, Professor de Medicina e Diretor da Divisão de Nefrologia e Hipertensão da Faculdade de Medicina da Universidade de Vermont. "O sistema no local de atendimento da MediBeacon pode representar um importante avanço na medição da função renal." "Estamos muito contentes com o progresso contínuo obtido pela MediBeacon na validação da sua tecnologia", afirmou Philip Falcone, Chairman, CEO e Presidente da HC2. "Ao longo do tempo, as inovações da MediBeacon têm tido o potencial de melhorar os cuidados ao paciente e de reduzir os custos para o sistema de saúde." As atuais aplicações da tecnologia MediBeacon têm vindo a ser investigadas nas áreas de saúde renal, permeabilidade gastrointestinal e angiografia ótica. O crescimento do portefólio de Propriedade Intelectual (PI) da empresa aumentou para 29 patentes atribuídas nos EUA, com 17 solicitações de patentes pendentes. Em setembro de 2016, a MediBeacon recebeu um subsídio do Instituto Nacional da Visão (NEI) dos Institutos Nacionais da Saúde (NIH) sob o Prémio Número R43EY027207. Com este apoio, a empresa procura investigar o uso do agente marcador fluorescente da MediBeacon para visualizar a vasculatura no olho. Em outubro de 2016, a MediBeacon, em colaboração com a Washington University, recebeu um subsídio de 1,1 milhões de dólares da Fundação Bill & Melinda Gates para um projeto de investigação destinado a melhorar o conhecimento da desnutrição infantil e dos problemas relacionados, incluindo o raquitismo. A missão da MediBeacon é a comercialização de agentes de diagnóstico ótico biocompatíveis para monitorização fisiológica, orientação cirúrgica e imagiologia de distúrbios patológicos na população humana. Diversos conceitos de produtos nestas áreas fazem parte do património de Propriedade Intelectual da MediBeacon. O portfólio da MediBeacon inclui um sistema de função renal que usa um sensor ótico de pele combinado com um agente marcador fluorescente proprietário que brilha na presença de luz. Este sistema, atualmente a ser testado em humanos, foi desenhado para fornecer aos profissionais de saúde uma monitorização contínua em tempo real da função renal do paciente. A HC2 Holdings, Inc. é uma empresa de holding diversificada e de capital aberto (NYSE MKT:HCHC), que procura oportunidades para adquirir e desenvolver negócios que possam gerar fluxo de caixa livre, sustentável e a longo prazo, além de rendimentos atrativos para maximização do valor para todos os acionistas. A HC2 conta com uma vasta gama de subsidiárias que operam em sete segmentos, incluindo Fabrico, Serviços Marítimos, Serviços Públicos, Telecomunicações, Ciências da Vida e Seguros, entre Outros. As maiores subsidiárias operacionais da HC2 incluem a DBM Global Inc., uma família de empresas que fornece serviços de construção estrutural em aço totalmente integrados e a Global Marine Systems Limited, um fornecedor líder de serviços de engenharia e subaquáticos em cabos submarinos. Fundada em 1994, a HC2 está sediada em Nova Iorque, Nova Iorque. Saiba mais sobre a HC2 e as empresas do seu portefólio em www.hc2.com


Ardura J.A.,Instituto Of Investigacion Sanitaria Iis Fundacion Jimenez Diaz | Sanz A.B.,Nefrologia | Ortiz A.,Autonomous University of Madrid | Esbrit P.,Instituto Of Investigacion Sanitaria Iis Fundacion Jimenez Diaz
Kidney International | Year: 2013

Runx2 is a key transcription factor in bone development regulating several processes, including osteoblast apoptosis. The antiapoptotic effects of parathyroid hormone (PTH) in osteoblasts depend on Runx2-mediated transcription of prosurvival genes. In the kidney, PTH-related protein (PTHrP) promotes tubulointerstitial cell survival by activating the PTH/PTHrP type 1 receptor. We found that Runx2 is expressed in renal tubuloepithelial MCT and HK2 cell lines in vitro and in the mouse kidney tubuloepithelium in vivo. The 1-36 amino-acid fragment of PTHrP was found to increase the expression and nuclear translocation of Runx2 in both cell lines in a dose-and time-dependent manner. PTHrP(1-36) protected renal tubuloepithelial cells from folic acid toxicity and serum deprivation, an effect inhibited by a dominant-negative Runx2 construct or a Runx2 siRNA. Furthermore, PTHrP(1-36) upregulated the antiapoptotic proteins Bcl-2 and osteopontin, and these effects were abolished by Runx2 siRNA. Runx2, osteopontin, and Bcl-2 were increased in tubuloepithelial cells from transgenic mice with PTHrP overexpression and in wild-type mice with acute or chronic renal failure. Thus, PTHrP regulates renal tubuloepithelial cell survival via Runx2 in the mammalian kidney. © 2013 International Society of Nephrology.


Fernandez-Sanchez A.,Hospital Universitario Central Of Asturias | Raneros A.B.,Hospital Universitario Central Of Asturias | Palao R.C.,Hospital Universitario Central Of Asturias | Sanz A.B.,Hospital Universitario La Paz | And 5 more authors.
Epigenetics | Year: 2013

The human activating receptor NKG2D is mainly expressed by NK, NKT, γδ T and CD8+ T cells and, under certain conditions, by CD4+ T cells. This receptor recognizes a diverse family of ligands (MICA, MICB and ULBPs 1-6) leading to the activation of effector cells and triggering the lysis of target cells. The NKG2D receptor-ligand system plays an important role in the immune response to infections, tumors, transplanted graft and autoantigens. Elucidation of the regulatory mechanisms of NKG2D is therefore essential for therapeutic purposes. In this study, we speculate whether epigenetic mechanisms, such as DNA methylation and histone acetylation, participate in NKG2D gene regulation in T lymphocytes and NK cells. DNA methylation in the NKG2D gene was observed in CD4+ T lymphocytes and T cell lines (Jurkat and HUT78), while this gene was unmethylated in NKG2D-positive cells (CD8+ T lymphocytes, NK cells and NKL cell line) and associated with high levels of histone H3 lysine 9 acetylation (H3K9Ac). Treatment with the histone acetyltransferase (HA T) inhibitor curcumin reduces H3K9Ac levels in the NKG2D gene, downregulates NKG2D transcription and leads to a marked reduction in the lytic capacity of NKG2D-mediated NKL cells. These findings suggest that differential NKG2D expression in the different cell subsets is regulated by epigenetic mechanisms and that its modulation by epigenetic treatments might provide a new strategy for treating several pathologies. © 2013 Landes Bioscience.


Neri L.,Saint Louis University | Neri L.,University of Milan | Martini A.,Nefrologia | Andreucci V.E.,Fondazione Italiana Del Rene Italian Kidney Foundation | And 3 more authors.
American Journal of Nephrology | Year: 2011

Objectives: Poor medication adherence is common in end-stage renal disease and may cause suboptimal outcomes and increased healthcare costs. We assessed the association between regimen complexity, perceived burden of oral therapy (BOT) and medication adherence in a large sample of hemodialysis (HD) patients. Methods: 1,238 HD patients in 54 Italian centers participated. Data were collected on patients' socio-demographic characteristics, perceived BOT, quality of life, healthcare satisfaction, social support and medication adherence with a self-administered questionnaire. Data on medication regimen, comorbidities, hospitalizations, and transplant listing status were provided by the nursing staff. We estimated the adjusted association of regimen complexity, BOT and medication adherence with logistic regression. Results: There were 789 (64%) men and the median age was 67 years. Mean daily burden was 9.7 tablets and 48% of patients were adherent to medication prescriptions. The number of tablets prescribed in the medication regimen was associated to adherence likelihood after adjustment for possible confounders. Perceived BOT moderated the association between tablet count and self-reported adherence. Conclusion: Poor adherence was very common in our sample. Reducing tablet burden might help patients be adherent. However, our results suggest that modulating regimen complexity might be ineffective if patients' negative attitudes toward medications are not addressed concurrently. Copyright © 2011 S. Karger AG, Basel.


Uremia associated with anticoagulant therapy is a high risk factor for bleeding complications in patients undergoing hemodialysis. We report a case of intrarenal hematoma arising in a uremic patient treated with warfarin. The hematoma was rapidly diagnosed by ultrasonography of the abdomen and treated with embolization. Our experience confirms that the availability of an ultrasound facility within the renal unit allows better assessment of our patients, also in the management of the most fearsome and rare complications. Moreover, it strengthens the evidence that uremic patients are at high risk of bleeding complications when treated with oral anticoagulants.


Piccoli G.B.,Nefrologia
Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia | Year: 2012

The evolution of home dialysis marked the main steps in the progress of renal replacement therapy. From the origins when home hemodialysis was often the only alternative to death, to the advent and widespread use of peritoneal dialysis, the dream of kidney transplant as a solution to all problems (at least in the young), and ultimately the profound social and organizational changes that have led to a drastic reduction of home hemodialysis, we arrive at the present with the rediscovery of the clinical, rehabilitative and economic advantages of home dialysis. Seven experts from five different centers with different expertise in home dialysis report their opinions on the future of home dialysis in a ''noncontroversial controversy''. Beyond the sterile competition between peritoneal dialysis and home hemodialysis, the shared opinion is that the two methods may complement each other, allowing a tailored treatment for each patient and a tailored organization in each setting. The organizational solutions are many; the authors underline the importance of longer survival and better rehabilitation, and the ethical need of offering each patient a choice among all available treatments. Add to this the importance of dedicated educational programs targeted to physicians, nurses and patients alike and focused on self-care and patient empowerment. A new generation of dialysis machines, easier technical solutions, and financial incentives may strengthen motivations and simplify problems; all these elements may in the near future be combined in a joint effort to increase peritoneal dialysis and revive home hemodialysis in Italy.


Dugo M.,Nefrologia
Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia | Year: 2010

The first reports of interstitial fibrosis leading to rapidly progressing chronic renal failure (CRF) in young women undergoing slimming treatment appeared at the beginning of the 1990s in Belgium. These slimming pills erroneously contained powdered roots of plants - picked in China - belonging to the Aristolochia instead of Stephania tetranda family. In the following years, after new cases had occurred worldwide, the term aristolochic acid nephropathy (AAN) came into use. Despite numerous warnings from various post-marketing surveillance institutes, products containing aristolochic acid are still widely used by Asiatic herbal practitioners and easily available on the Internet, where they are marketed without being subject to any regulations. In 2002 the IARC (International Agency for Research on Cancer) conclusively recognized the urothelial carcinogenicity of aristolochic acid. Because of the globalization and the growing use of phytotherapy worldwide, nephrologists should take into account AAN as a possible cause of CRF. In addition to assessing the direct kidney toxicity caused by some products used in phytotherapy, the authors conclude that it is necessary to research more closely possible drug interactions and side effects of commonly used herbs such as Echinacea, Gingko biloba, St. John's wort, ginseng, and garlic, which patients consider to be natural, non-toxic and self-prescribed remedies and whose use they therefore seldom disclose to their doctors.


Pani A.,Nefrologia
Autoimmunity Reviews | Year: 2013

Glomerulonephritis (GN) accounts for 10%-20% of the total incident cases of end stage renal disease (ESRD), and is the third most common cause of ESRD after diabetes and hypertension in western countries. The pathogenesis of glomerulonephritis is prevalently immune mediated: humoral and cell-mediated immunity are involved, although the rationale for an etiological treatment is still lacking. In the last forty years, empirical treatment based upon the use of corticosteroids and/or immunosuppressive drugs have obtained excellent results in improving survival of both the patient and the kidney. Almost 95% of children affected by minimal change disease (MCD) achieve remission of proteinuria within 4 to 8. weeks of prednisone administration. In adults with focal segmental glomerulosclerosis (FSGS), prednisone induces complete or partial remission in the majority of patients, but a longer period of steroid treatment or the combination of calcineurin inhibitors or cytotoxic drugs can be needed. A percentage of 65%-70% of patients with idiopathic membranous nephropathy (MN) reach complete or partial remission with a 6-month course of therapy alternating glucocorticoids with alkylating agents. Glucocorticoids plus cyclophosphamide, and, on occasion, plasmapheresis are effective in 70%-90% of patients with ANCA-associated vasculitis (AAV). Fifty percent of responders relapse within the 3-5. years and currently, the mortality of AAV at 1. year exceeds 15%.This article is aimed to analyze the risk-to-benefit balance of steroids and conventional immunosuppressive regimens, focusing, for a sake of brevity, on idiopathic nephrotic syndrome (INS) and ANCA associated vasculitis. © 2012.


Bonucchi D.,Nefrologia
Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia | Year: 2010

Lupus nephritis (LN) seldom recurs in a grafted kidney. By contrast, primary membranoproliferative glomerulonephritis (MPGN), which has been included, along with hemolytic uremic syndrome and age-related maculopathy, among the complement dysregulation diseases, has a high recurrence rate and is considered a contraindication to living-donor kidney transplant because of the poor prognosis. We report the case of a young girl with LN-related chronic renal failure who underwent a living donor transplant from her mother. After four months she had a recurrence that did not match the criteria for LN. Graft biopsies and revision of the clinical course pointed to type II MPGN on the basis of a lack of ARA criteria, persistent isolated low C3 levels, and response to plasma therapy. If confirmed by genetic analysis, the patient might benefit from treatment with the monoclonal antibody against the C5-C9 complex, eculizumab.


Viglino G.,Nefrologia | Neri L.,Nefrologia | Feola M.,Riabilitazione Cardiologica Unita Scompenso Cardiaco
Journal of Nephrology | Year: 2015

Introduction: Peritoneal ultrafiltration (PUF) is proposed in the long-term treatment of congestive heart insufficiency. However, the data in literature available at present do not allow for conclusive meta-analysis.Objective/materials and methods: A systematic review of the literature (MEDLINE–EMBASE, 01/01/2003–31/12/2013, studies with ≥4 patients, adults, non-ESRD) to highlight which patients PUF has been used in, how and with what results.Results: Consideration was given to 14 papers for a total of 471 patients. (1) Characteristics of the patients. Average age 71.6 years; diabetes mellitus (DM) 47 %; New York Heart Association (NYHA) class III 38.9 %–class IV 59.8 %; ischemic cardiopathy 67.8 %; mean LVEF 35 %. (2) PUF modality. Only continuous ambulatory peritoneal dialysis (CAPD) in ten studies, only APD in two studies, both in two studies. Overall CAPD was used in 56.2 % of the pts. A single exchange of icodextrin was used to treat 51 % of patients on CAPD. The volume of ultrafiltration obtained varied between 390 and 1,180 ml/die. (3) Effects of PUF. Significant improvement in NYHA class and reduction in hospitalizations. Survival at 12 months varying between 47 and 95 %. Mortality seems to be associated with DM, higher basal glomerular filtration rate, less change in ejection fraction after PUF and less use of ICOs.Limitation: The main limitation of the selected studies, mostly retrospective and with a limited number of patients, remains the lack of clarity and uniformity of the selection criteria used. For this reason extrapolations about survival require extreme caution and are not currently possible.Conclusions: PUF improves symptomatology and reduces hospitalizations. © 2014, Italian Society of Nephrology.

Loading Nefrologia collaborators
Loading Nefrologia collaborators